When Sun Protection Begets Malnutrition: Vitamin D Deficiency in Japanese Women
November 22, 2024
Omega-3 Shows Potential For Improved Insulin Sensitivity
November 29, 2024

Robert F. Kennedy Jr.’s Billion-Dollar Hit to Big Pharma

Share this post:

News

Shares in big vaccine producers, including Pfizer and Moderna, tumbled soon after Donald Trump named Robert F. Kennedy Jr. as his choice to lead the Department of Health and Human Services.
[Source: nytimes.com]

[Image source: Wikimedia]

Comment

Robert F. Kennedy Jr.’s nomination quickly sparked panic among investors in the pharmaceutical and biotech industries. Shares of major vaccine manufacturers saw sharp declines, with an estimated $8 billion in market value wiped out. Drug, vaccine, and chemical investors are worried that Kennedy has pledged to address corruption and industry influence within America’s health agencies. He has also expressed skepticism about certain vaccines and pharmaceuticals, as well as over substances such as pesticides and food additives.

After playing a key role supporting the latter stages of Trump’s election campaign, Kennedy now appears poised to exert substantial influence in reshaping America’s health policy. What is already certain is that he will face significant opposition, not only from within U.S. government agencies but also from the pharmaceutical, biotech, and chemical industries. Overcoming this will not be easy.

To read how Kennedy has said he wants to clear out entire departments at the U.S. Food and Drug Administration (FDA), see this news story on our website.

Share this post: